Article in Biospace.com, the most comprehensive Life Science industry news and information source
Excerpt
Alzheon’s lead compound, ALZ-801, received Fast Track designation from the U.S. Food and Drug Administration in 2017. It will begin the Phase III APOLLOE4 trial in the second quarter of this year to halt disease progression among early Alzheimer’s disease patients who have two copies of the apolipoprotein E4 gene (APOE4/4).
The ALZ-801 program may be expanded in the future to healthy individuals to prevent Alzheimer’s disease onset, and to early Alzheimer’s patients who carry only one copy of the APOE4 gene.
Read the full article here